2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 84

Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome

SLE – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 448

Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 546

Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 780

Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 797

Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 714

Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry

Systemic Sclerosis & Related Disorders – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 529

Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators

RA – Treatments Poster I: Novel Treatments

9:00AM-11:00AM: Abstract Number: 96

Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 9

Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus

Cytokines & Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 749

Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 746

Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK

Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 56

Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly

RA – Etiology & Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 773

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 402

Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 256

Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States

Health Services Research Poster I – ACR/ARP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].